Optimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulation

European Journal of Clinical Pharmacology

Volumn 68, Issue 1, 2012, Pages 39-53

  Tanigawara, Yusuke ^a   Nozawa, Kenji ^b   Tsuda, Hisatsugu ^b  

^a KEIO UNIVERSITY   (Japan)

^b TOYAMA CHEMICAL CO LTD   (Japan)

Author keywords

Dose finding; Garenoxacin; Model based drug development; Monte Carlo simulation; Pharmacodynamics; Population pharmacokinetics

Indexed keywords

GARENOXACIN;

ADULT; AGED; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHRONIC RESPIRATORY TRACT DISEASE; CONTROLLED STUDY; DOSE CALCULATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; OPTIMAL DRUG DOSE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; INTESTINAL ABSORPTION; MALE; METABOLIC CLEARANCE RATE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PHARMACOLOGY, CLINICAL; RESPIRATORY TRACT INFECTIONS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84857048793     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1095-3     Document Type: Article

References (35)

1. JC Fung-Tomc B Minassian B Kolek E Huczko L Aleksunes T Stickle T Washo E Gradelski L Valera DP Bonner 2000 Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756 Antimicrob Agents Chemother 44 3351 3356 11083639 10.1128/AAC.44.12.3351-3356.2000 1:CAS:528:DC%2BD3MXhs1Kit7s%3D (Pubitemid 33009494)
2. M Takahata J Mitsuyama Y Yamashiro M Yonezawa H Araki Y Todo S Minami Y Watanabe H Narita 1999 In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone Antimicrob Agents Chemother 43 1077 1084 10223917 1:CAS:528:DyaK1MXjtVejsrw%3D (Pubitemid 29214728)
3. GG Zhanel L Palatnick KA Nichol T Bellyou DE Low DJ Hoban 2003 Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian respiratory organism susceptibility study, 1997 to 2002 Antimicrob Agents Chemother 47 1867 1874 12760860 10.1128/AAC.47.6.1867-1874. 2003 1:CAS:528:DC%2BD3sXktlymtLo%3D (Pubitemid 36637807)
4. GG Zhanel L Palatnick KA Nichol DE Low The CROSS Study Group DJ Hoban 2003 Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian respiratory organism susceptibility study, 1997 to 2002 Antimicrob Agents Chemother 47 1875 1881 12760861 10.1128/AAC.47.6.1875-1881.2003 1:CAS:528:DC%2BD3sXktlymtLs%3D (Pubitemid 36637808)
5. M Takahata Y Fukuda N Futakuchi Y Sugiura H Hisada S Mizunaga N Oogake Y Ito Y Shinmura M Nakatani T Tanaka T Komeno T Kamiyama J Mitsuyama Y Todo 2007 In vitro antibacterial activity of garenoxacin Chemotherapy (Tokyo). 55 Suppl. 1 1 20 1:CAS:528:DC%2BD2sXht1als7%2FO (Pubitemid 47604074)
6. Y Niki A Watanabe N Aoki S Kohno 2003 Dose-finding study on telithromycin in bacterial pneumonia Chemotherapy (Tokyo). 51 Suppl 1 240 254 (Pubitemid 37322301)
7. A Saito A Watanabe S Odagiri N Aoki T Matsushima M Nasu M Nakashima K Yamaguchi J Shimada 2005 A dose-finding study on doripenem in chronic respiratory tract infection Chemotherapy (Tokyo). 53 Suppl 1 169 184 (Pubitemid 41093800)
8. PG Ambrose SM Bhavnani CM Rubino A Louie T Gumbo A Forrest GL Drusano 2007 Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore Clin Infect Dis 44 79 86 17143821 10.1086/510079 1:CAS:528:DC%2BD2sXnvVCjtA%3D%3D (Pubitemid 44968990)
9. JW Mouton 2003 Impact of pharmacodynamics on breakpoint selection for susceptibility testing Infect Dis Clin North Am 17 579 598 14711078 10.1016/S0891-5520(03)00062-X (Pubitemid 38029154)
10. A Forrest DE Nix CH Ballow TF Goss MC Birmingham JJ Schentag 1993 Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients Antimicrob Agents Chemother 37 1073 1081 8517694 1:STN:280:DyaK3s3psl2htg%3D%3D (Pubitemid 23141323)
11. SV Van Wart L Phillips EA Ludwig R Russo DA Gajjar A Bello PG Ambrose C Costanzo TH Grasela R Echols DM Grasela 2004 Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections Antimicrob Agents Chemother 48 4766 4777 15561855 10.1128/AAC.48.12.4766-4777.2004 (Pubitemid 39577683)
12. D Andes WA Craig 2003 Pharmacodynamics of the new des-F(6)-quinolone garenoxacin in a murine thigh infection model Antimicrob Agents Chemother 47 3935 3941 14638504 10.1128/AAC.47.12.3935-3941.2003 1:CAS:528: DC%2BD3sXpsV2nu7s%3D (Pubitemid 37485010)
13. X Zhao K Drlica 2001 Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies Clin Infect Dis 33 S147 S156 11524712 10.1086/321841 1:CAS:528:DC%2BD3MXnt12mtLw%3D (Pubitemid 32835784)
14. K Drlica 2003 The mutant selection window and antimicrobial resistance J Antimicrob Chemother 52 11 17 12805267 10.1093/jac/dkg269 1:CAS:528: DC%2BD3sXltVSqtbY%3D (Pubitemid 36850078)
15. GL Drusano 2004 Antimicrobial pharmacodynamics: critical interactions of 'bug and drug' Nat Rev Microbiol 2 289 300 15031728 10.1038/nrmicro862 1:CAS:528:DC%2BD2cXit12nt74%3D (Pubitemid 39490099)
16. H Kobayashi A Watanabe N Aoki S Odagiri Y Sano A Saito 2007 Clinical phase II study of garenoxacin in patients with respiratory tract infections Chemotherapy (Tokyo) 55 Suppl 1 116 126
17. H Kobayashi Y Tanigawara A Watanabe N Aoki Y Sano S Odagiri Y Niki S Kohno A Saito 2007 Phase III study of garenoxacin in patients with secondary infection of chronic respiratory diseases Chemotherapy (Tokyo) 55 Suppl.1 144 161 (Pubitemid 47604084)
18. E Uchida 2007 Phase I clinical studies of oral garenoxacin in healthy Japanese adult subjects Chemotherapy (Tokyo). 55 Suppl. 1 95 115 1:CAS:528:DC%2BD2sXht1als7zO (Pubitemid 47604082)
19. H Fukumoto H Matsutani Y Yamamoto H Sakai 2003 Determination of garenoxacin and its sulfate conjugate metabolite in human plasma and urine using liquid chromatography-mass spectrometry Iyakuhin Kenkyu (Tokyo). 34 153 163 1:CAS:528:DC%2BD3sXjt1Wqsro%3D
20. Japan Society of Chemotherapy 1981 Method of MIC determination Chemotherapy (Tokyo). 29 76 79
21. Clinical and Laboratory Standards Institute (2005) Performance standards for antimicrobial susceptibility testing. Document M100-S15. CLSI, Wayne
22. Sheiner LB, Beal SL (eds) (1998) NONMEM user's guide, part V. University of California, San Francisco
23. DW Cockcroft MH Gault 1976 Prediction of creatinine clearance from serum creatinine Nephron 16 31 41 1244564 10.1159/000180580 1:STN:280: DyaE28%2FnsF2isw%3D%3D
24. Efron B, Tibshirani RJ (1993) An introduce to the bootstrap. Chapman & Hall, New York
25. X Zhao W Eisner NP Rosenthal B Kreiswirth K Drlica 2003 Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus Antimicrob Agents Chemother 47 1023 1027 12604537 10.1128/AAC.47.3.1023-1027.2003 (Pubitemid 36254230)
26. X Li N Mariano JJ Rahal CM Urban K Drlica 2004 Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin Antimicrob Agents Chemother 48 4460 4462 15504883 10.1128/AAC.48.11.4460-4462.2004 1:CAS:528:DC%2BD2cXpvVyktL4%3D (Pubitemid 39434917)
27. JW Mouton MN Dudley O Cars H Derendorf GL Drusano 2005 Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update J Antimicrob Chemother 55 601 607 15772142 10.1093/jac/dki079 1:CAS:528:DC%2BD2MXjvFymtbg%3D (Pubitemid 40691835)
28. N Miyashita T Matsushima M Oka JR Society 2006 The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations Intern Med. (Tokyo). 45 419 428 10.2169/internalmedicine.45.1691 (Pubitemid 43676577)
29. R Sato Y Tanigawara M Kaku N Aikawa K Shimizu 2006 Pharmacokinetic- pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 50 3763 3769 17065622 10.1128/AAC.00480-05 1:CAS:528:DC%2BD28XhtFOkt7nI (Pubitemid 44684891)
30. Y Tanigawara R Sato K Morita M Kaku N Aikawa K Shimizu 2006 Population pharmacokinetics of arbekacin in patients infected with methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 50 3754 3762 17065621 10.1128/AAC.00420-05 1:CAS:528:DC%2BD28XhtFOkt7nP (Pubitemid 44684890)
31. GP Allen GW Kaatz MJ Rybak 2003 Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model Antimicrob Agents Chemother 47 2606 2614 12878526 10.1128/AAC.47.8.2606-2614.2003 1:CAS:528: DC%2BD3sXlvFCls7w%3D (Pubitemid 36919466)
32. Blondeau J, Borsos S, Hedlin P, Hansen G (2003) Determination of the minimal inhibitory concentration (MIC) and mutation prevention concentration (MPC) for garenoxacin against clinical isolates of Streptococcus pneumoniae. In: Raoult D (ed) Poster No. P1540 presented at 13th European Congress of Clinical Microbiology and Infectious Diseases, 2003. Clin Microbiol Infect 9(1):375. John Wiley & Sons, Inc., pp 1-422
33. T Homma T Hori G Sugimori Y Yamano 2007 Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae Antimicrob Agents Chemother 51 3810 3815 17664314 10.1128/AAC.01372-06 1:CAS:528:DC%2BD2sXht1ygtL7M (Pubitemid 350057775)
34. VH Tam A Louie MR Deziel W Liu R Leary GL Drusano 2005 Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa J Infect Dis 192 420 428 15995955 10.1086/430611 (Pubitemid 41023120)
35. G Krishna D Gajjar S Swan T Marbury DM Grasela Z Wang 2007 Garenoxacin pharmacokinetics in subjects with renal impairment Curr Med Res Opin 23 649 657 17355746 10.1185/030079906X167679 1:CAS:528:DC%2BD2sXkt1Wrsr0%3D (Pubitemid 46456913)